Mitotic count can predict tamoxifen benefit in postmenopausal breast cancer patients while Ki67 score cannot

BACKGROUND: Controversy exists for the use of Ki67 protein expression as a predictive marker to select patients who do or do not derive benefit from adjuvant endocrine therapy. Whether other proliferation markers, like Cyclin D1, and mitotic count can also be used to identify those estrogen receptor...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:BMC Cancer
Päätekijät: Beelen, Karin, Opdam, Mark, Severson, Tesa, Koornstra, Rutger, Vincent, Andrew, Wesseling, Jelle, Sanders, Joyce, Vermorken, Jan, van Diest, Paul, Linn, Sabine
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: BioMed Central 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6057037/
https://ncbi.nlm.nih.gov/pubmed/30041599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4516-1
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia